Immunic, Inc. is a biotechnology company based in New York, NY, focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Their mission is to provide high-quality, oral treatment options with comprehensive therapeutic efficacy and outstanding safety for patients suffering from conditions such as multiple sclerosis and celiac disease.
With a team dedicated to developing ground-breaking technologies and bringing life-changing therapies to patients, Immunic aims to improve the lives of individuals affected by debilitating diseases by offering new, efficacious, and well-tolerated treatment options. Their drug candidates are designed to combine the convenience of oral delivery with robust efficacy and patient-friendly tolerability, ultimately striving to maximize benefits for patients and create long-term value for stakeholders.
Generated from the website